Penumbra Inc Stock Price, News & Analysis

Penumbra (NYSE:PEN), a leading thrombectomy company, reported strong Q2 2025 financial results with revenue of $339.5 million, up 13.4% year-over-year. The company demonstrated robust performance in key segments, with U.S. Thrombectomy revenue reaching $188.5 million, a 22.6% increase, and U.S. VTE revenue growing 42% compared to Q2 2024.

The company achieved net income of $45.3 million with a 13.3% margin and adjusted EBITDA of $61.4 million with an 18.1% margin. Gross profit improved to $224.0 million with a 66.0% margin. Based on strong performance, Penumbra increased its 2025 revenue guidance to $1.355-1.370 billion, representing 13-15% growth over 2024.

Penumbra (NYSE: PEN) has scheduled its second quarter 2025 earnings conference call for July 29, 2025, at 4:30 PM Eastern Time. The company will release its Q2 2025 financial results after market close on the same day.

Investors can access the conference call by dialing (888) 596-4144 with conference ID 6572573, or via webcast through the "Events and Presentations" section on Penumbra's website. The webcast recording will remain available for at least two weeks after the call.

Penumbra (NYSE: PEN) has completed enrollment for its STORM-PE clinical trial, a landmark study evaluating computer assisted vacuum thrombectomy (CAVT) using Lightning Flash technology. The trial enrolled 100 patients to compare CAVT plus anticoagulation versus anticoagulation alone in treating acute intermediate-high risk pulmonary embolism. The study, conducted with The PERT Consortium, aims to provide Level 1 clinical evidence for treatment guidelines. Notably, pulmonary embolism affects approximately 900,000 cases annually in the U.S., with 10-30% mortality rate within one month of diagnosis. The Lightning Flash portfolio features dual clot detection algorithms and MaxID hypotube technology, designed for efficient blood clot removal with enhanced navigation capabilities.

Penumbra (NYSE: PEN) has received FDA clearance and launched the Ruby XL System, introducing the market's longest, largest, and softest coil for vascular embolization. The system features three innovative technologies: Ruby XL, POD XL, and Packing Coil XL, all deliverable through a 0.035"+ diagnostic catheter. These coils offer unprecedented volume (up to 40mm size) and extended lengths up to 70 cm, with a primary diameter of .030". The Ruby XL System aims to enhance procedural efficiency, potentially reduce radiation exposure, and optimize outcomes in large vessel and high-flow embolization procedures. The technology includes specialized features like 3D complex shapes for aneurysm framing, hybrid multistage design for targeted vessel control, and innovative liquid metal wave shape technology for dynamic vessel adaptation.

Penumbra Inc (NYSE: PEN) has announced its management team's participation in three upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference on June 3 at 3:00pm ET
• Jefferies Global Healthcare Conference on June 4 at 9:55am ET
• Truist Securities MedTech Conference on June 17 at 10:00am ET

Webcasts of the presentations will be accessible through the "Events and Presentations" section under the "Investors" tab on Penumbra's website and will remain available for at least two weeks after each event.

Penumbra (NYSE: PEN) has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The company's management team will deliver a presentation on Tuesday, May 13, 2025, at 6:00pm ET/3:00pm PT.

Interested parties can access a live webcast of the presentation through the "Events and Presentations" section under the "Investors" tab on Penumbra's official website. The recorded presentation will remain available for viewing on the company's website for a minimum of two weeks following the event.

Penumbra (NYSE: PEN) reported strong Q1 2025 financial results with total revenue reaching $324.1 million, up 16.3% year-over-year. The company's U.S. Thrombectomy segment showed remarkable growth of 25%, generating revenue of $187.9 million.

Key financial metrics include:

• Operating income of $40.4 million with 12.4% margin
• Net income of $39.2 million with 12.1% margin
• Adjusted EBITDA of $59.6 million with 18.4% margin
• Gross profit of $215.9 million with 66.6% margin

The company maintains its 2025 revenue guidance of $1,340-1,360 million while raising U.S. Thrombectomy growth guidance to 20-21%. Management expects gross margin expansion of at least 100 basis points to over 67% and operating margin of 13-14% for full year 2025.

Penumbra (NYSE: PEN) has scheduled its first quarter 2025 earnings release and conference call for April 23, 2025. The company will release its Q1 2025 financial results after market close, followed by a conference call at 4:30 PM Eastern Time.

Investors and interested parties can access the conference call by dialing (888) 596-4144 with conference ID 6572573, or via webcast through the 'Events and Presentations' section on Penumbra's website. The webcast recording will remain available for a minimum of two weeks after the call.

Penumbra (NYSE: PEN) presented seven new data sets demonstrating the effectiveness of their Computer Assisted Vacuum Thrombectomy (CAVT™) technology at the 2025 Society of Interventional Radiology Annual Meeting. The STRIKE-PE trial showed significant improvements in treating pulmonary embolism, with a 27.8% reduction in right ventricle/left ventricle ratio and 24.5% decrease in pulmonary artery pressures, while maintaining a low adverse event rate under 1%.

The STRIDE study demonstrated high limb salvage rates for lower-extremity acute limb ischemia. The THRIVE study revealed CAVT resulted in 26-46% shorter hospital stays and 46-75% higher home discharge rates compared to traditional treatments. For lower extremity venous thrombus treatment, CAVT showed 17% shorter hospital stays and 40% higher home discharge rates versus anticoagulation alone.